EpicentRx begins Phase 3 REPLATINUM study of lead program RRx-001 in Small Cell Lung Cancer

Minimally toxic therapies for innate and adaptive immunity against cancer.

Toxicity to Tumors not to Patients

EpicentRx is developing new mechanisms of immunotherapy that act alone or in combination with other medicines to outsmart cancer with minimal toxicity across diverse patient populations and tumor types.

MAX-INNATE Platform

EpicentRx’s lead program is RRx-001, a next generation small molecule immunotherapeutic in the Phase 3 REPLATINUM trial to treat small cell lung cancer.

ADAPTIGENE Platform

EpicentRx is developing the first ever series of oncolytic viruses tailored to tumors of individual patients.

RECENT NEWS

December 4, 2019

EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer

November 25, 2019

EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma

November 13, 2019

EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform

November 05, 2019

EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer

June 25, 2019

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

May 02, 2018
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines

View all